3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
8
Leukemia, Myeloid, Chronic-Phase
6
Blast Crisis
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Sarcoma
4
Melanoma
4
Gastrointestinal Stromal Tumors
4
Leukemia, Myeloid, Accelerated Phase
3
Sarcoma, Synovial
2
Oligodendroglioma
2
Leukemia, Myeloid, Acute
2
Glioma
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Uterine Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Refractory Desmoplastic Small Round Cell Tumors
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Piebaldism
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Neurofibromatoses
1
Interventions
Cisplatin
3
Amifostine
3
Radiotherapy
2
Paclitaxel
2
sodium thiosulfate
1
selinexor
1
Trastuzumab
1
Topotecan
1
Pharmaceutical Preparations
1
Nivolumab
1
Methotrexate
1
Imatinib Mesylate
1
Filgrastim
1
Etoposide
1
Drug Combinations
1
Doxorubicin
1
Docetaxel
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Drug-Related Side Effects and Adverse Reactions
×
Imatinib Mesylate
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled